- Home
- BHVN
BHVN
Biohaven Ltd.
as 08-22-2025 4:00pm EST
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | NEW HAVEN |
| Market Cap: | 1.5B | IPO Year: | 2017 |
| Target Price: | $54.62 | AVG Volume (30 days): | 2.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 14 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -7.65 | EPS Growth: | N/A |
| 52 Week Low/High: | $12.79 - $55.70 | Next Earning Date: | 08-11-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 1007.82% |
Latest Biohaven Ltd. News
BHVN Breaking Stock News: Dive into BHVN Ticker-Specific Updates for Smart Investing
Simply Wall St.
2 months ago
Biohaven Insiders Added US$6.28m Of Stock To Their Holdings
GlobeNewswire
2 months ago
Bexorg Announces Research Collaboration with Biohaven Leveraging Its Novel AI-Driven Whole-Brain Discovery Platform to Enhance CNS Drug Development
PR Newswire
3 months ago
Biohaven Enrolls First Patient into Phase 2/3 Trial in Early Parkinson's Disease, Targeting Neuroinflammation with Novel Brain-Penetrant TYK2/JAK1 Inhibitor
Insider Monkey
3 months ago
Biohaven Ltd. (BHVN)’s BHV-1400 Cuts Disease Antibody by 81% in IgA Nephropathy
PR Newswire
3 months ago
Biohaven Highlights Innovation and Advancement Across MoDE and TRAP Degrader Platform at R&D Day, Announcing Positive TRAP Degrader Data Achieving > 80% Sustained Reductions in Galactose-Deficient IgA1 (Gd-IgA1) with Potential First-in-Class BHV-1400 for IgA Nephropathy (IgAN)
PR Newswire
3 months ago
Biohaven Presents Oncology Program Updates and Preliminary Clinical Data Showcasing Innovative Trop2 and FGFR3 Antibody Drug Conjugates (ADCs) Incorporating Novel TopoIx Payload with Potential to Treat a Wide Variety of Tumors
Motley Fool
3 months ago
Why Biohaven Stock Dove by Nearly 20% on Thursday
Investor's Business Daily
3 months ago
Biohaven Plunges On A Surprise FDA Twist For Its Rare-Disease Drug
Compare BHVN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BHVN Biohaven Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.